Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Delivra Health Brands Inc. (DHB.V)
CAD0.10
+0.00 (+0.00%)
CA TSXV Healthcare Drug Manufacturers - Specialty & Generic
Address
999 Canada Place V6C 3E1
Vancouver, BC, CA
Vancouver, BC, CA
CEO
Gord Davey
Website
delivrahealthbrands.com
IPO
2017-03-31
ISIN CA24703H2019
Also trades on
Other OTC · DHBUF (USD)
Toronto Stock Exchange Ventures · DHB.V (CAD)
Description
Based in Vancouver, Canada, Delivra Health Brands Inc., through its various subsidiaries, distributes an assortment of lifestyle and wellness goods to a global clientele of consumers and medical patients within regulated jurisdictions. The firm's product line includes cannabis, liquid sleep supplements, powdered sleep aids, edible gummies, and topical pain relief solutions. These items are available under well-known brand labels like LivRelief, Dream Water, and LivRelief Infused. The company was formerly recognized as Harvest One Cannabis Inc.
News Sentiment (7d)
Based on only 1 article — low confidence
- Delivra Health Brands launches LivRelief Itch Cream - ICYMI Proactive Investors - Finance
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CAD0.10
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
18.6K
Beta
0.89
Float Shares
13.88M
Free Float %
44.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -14.29% | -40.00% | -26.83% | -31.82% | +0.00% | -83.33% | -66.48% | -98.32% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.10
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-31.13
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+8.0% ★ Q1'26: -59.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-224.1% Q1'26: -143.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-9.6% Q1'26: -67.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-6.3% Q1'26: -78.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-27.6% Q1'26: -148.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+9.4% Q1'26: -25.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.95× ★ Q1'26: -0.60× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
726.0K
est: 922.5K (-21.3%)
|
5.98M
est: 922.5K (+548.5%)
|
7.78M
est: 11.47M (-32.1%)
|
7.96M
est: 12.60M (-36.9%)
|
8.14M
est: 25.60M (-68.2%)
|
9.79M
est: 8.87M (+10.4%)
|
12.38M
est: 12.44M (-0.5%)
|
13.37M
est: 12.99M (+2.9%)
|
12.84M
12.84M – 12.84M
-1.2% YoY
|
14.12M
14.12M – 14.12M
+10.0% YoY
|
| EBITDA |
-10.25M
est: -192.5K (-5,223.6%)
|
-25.40M
est: -192.5K (-13,093.5%)
|
-55.40M
est: -2.39M (-2,215.4%)
|
-7.04M
est: -2.63M (-167.9%)
|
-4.26M
est: -5.34M (+20.4%)
|
1.40M
est: -1.85M (+175.4%)
|
2.35M
est: -2.60M (+190.7%)
|
427.0K
est: -2.71M (+115.8%)
|
-2.68M
-2.68M – -2.68M
+1.2% YoY
|
-2.95M
-2.95M – -2.95M
-10.0% YoY
|
| EBIT |
-10.71M
est: -323.8K (-3,206.3%)
|
-26.21M
est: -323.8K (-7,993.6%)
|
-57.74M
est: -4.02M (-1,334.9%)
|
-9.26M
est: -4.42M (-109.4%)
|
-6.37M
est: -8.98M (+29.1%)
|
66.0K
est: -3.11M (+102.1%)
|
1.05M
est: -4.36M (+123.9%)
|
-841.0K
est: -4.56M (+81.6%)
|
-4.50M
-4.50M – -4.50M
+1.2% YoY
|
-4.96M
-4.96M – -4.96M
-10.0% YoY
|
| Net Income |
-12.61M
est: -2.66M (-374.4%)
|
-27.85M
est: -26.57M (-4.8%)
|
-79.86M
est: -46.89M (-70.3%)
|
-28.54M
est: -31.26M (+8.7%)
|
-7.01M
est: -3.13M (-124.2%)
|
-184.0K
|
876.0K
est: -312.6K (+380.2%)
|
-1.19M
est: -1.44M (+17.2%)
|
-250.1K
-250.1K – -250.1K
+82.6% YoY
|
312.6K
312.6K – 312.6K
+225.0% YoY
|
| SGA |
11.45M
est: 619.1K (+1,749.1%)
|
19.77M
est: 619.1K (+3,094.0%)
|
13.90M
est: 7.69M (+80.6%)
|
8.89M
est: 8.46M (+5.2%)
|
6.50M
est: 17.18M (-62.2%)
|
4.86M
est: 5.95M (-18.4%)
|
5.80M
est: 8.34M (-30.5%)
|
6.35M
est: 8.72M (-27.1%)
|
8.61M
8.61M – 8.61M
-1.2% YoY
|
9.47M
9.47M – 9.47M
+10.0% YoY
|
| EPS |
-1.05
est: -0.09 (-1,135.3%)
|
-1.45
est: -0.85 (-70.6%)
|
-2.66
est: -1.50 (-77.3%)
|
-1.00
est: -1.00 (+0.0%)
|
-0.28
est: -0.10 (-180.0%)
|
-0.01
|
0.03
est: -0.01 (+407.0%)
|
-0.04
est: -0.05 (+17.2%)
|
-0.01
-0.01 – -0.01
+82.6% YoY
|
0.01
0.01 – 0.01
+225.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
293.8K
OE per share TTM
0.01
Owner's Yield
6.26%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
78.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-38.2K
Shares Outstanding
31.26M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gord Davey | President, Chief Executive Officer & Director | 450.4K | male |
| Jack Z. Tasse | Chief Financial Officer & Corporate Secretary | 307.1K | male |
| Frank A. Holler | Independent Executive Chairman | 120.0K | male |
| Ann Gallery | Senior Vice President of Corporate Communications | — | female |
| Jonathan David Hartshorn | President & Chief Executive Officer of Satipharm | — | male |
| Tim Young | Senior VP & General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DHB.V
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
